Video description: DCA, metformin and low-dose navitoclax in old mice
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedThe description presents a three-drug combination (DCA, metformin, low-dose navitoclax) said to selectively kill senescent and cancer cells and to extend post-treatment lifespan by 41.7% in old mice, without added frailty or platelet toxicity. These are described preclinical mouse and cell-line results, not established human benefits. [1]
The description says cancer and senescent cells share damaged mitochondria and a reliance on glycolysis, which DCA and metformin are said to exploit. [1]
A ten-fold lower navitoclax dose is said to trigger selective apoptosis while sparing healthy human tissues and platelets. [1]
Intermittent dosing in 18-month-old mice reportedly extended post-treatment lifespan by 41.7% (+102 days) with improved treadmill endurance and no increase in frailty. [1]
Shared metabolic vulnerability in cancer and senescent cells
According to the description, cancer and senescent cells share a metabolic weakness: damaged mitochondria and a rigid reliance on glycolysis. DCA is said to push pyruvate into damaged mitochondria, while metformin inhibits Complex I ATP synthesis; together they form a metabolic vise that drains energy in these cells. The description attributes this account to Dr. Irina Conboy and her lab's 2026 paper in Aging. [1]
Low-dose navitoclax and 41.7% longer post-treatment lifespan in old mice
The description says first-generation senolytics like navitoclax (ABT-263) were potent but caused severe side effects such as platelet destruction (thrombocytopenia). With the metabolic combination, a ten-fold lower navitoclax dose is said to trigger selective apoptosis while sparing healthy human tissues and platelets. In 18-month-old mice given the drugs intermittently, post-treatment lifespan reportedly rose by 41.7% (+102 days), with improved treadmill endurance and no increase in frailty. [1]
Cell-line checks and a proposed injectable, not human outcomes
The description mentions selective apoptosis verified across diverse human cell lines and a planned Generation Lab pharmacological injectable intended to replace invasive therapeutic plasma exchange (TPE). It also notes a clinical pipeline of FDA trials for age-related diseases and warns about replicating the protocol at home with over-the-counter DCA. The described lifespan and endurance results come from old mice; the human cell-line work is laboratory evidence, and the injectable is presented as upcoming, not as a validated product. [1]
Context & limits
This is a video description only; the video and transcript were not reviewed. All findings are attributed to the description and creator. The lifespan, endurance and safety results come from old mice and human cell lines, not from human trials; the injectable is described as upcoming, not validated.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
damaged, short-circuiting mitochondria and an inflexible reliance
a 10-fold reduced dose of Navitoclax triggers
extended post-treatment lifespan by 41.7% (+102 days)
About this video
Creator description · original textText language: English
Modern Healthspan · 52 min · Source published: 2026-09-25
Added to Harbor: 10/23/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.